Skip to content

Alloy Therapeutics

1 viewer · 30d

Total raised

$30.0M

+$30.0M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $30.0M
ROUNDS
1
INVESTORS
11
FOUNDED
N/A
HQ
Waltham, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Alloy Therapeutics is a biotechnology company that licenses foundational drug-discovery platforms and runs discovery programs for pharmaceutical and biotech partners. Its flagship ATX-Gx platform is a set of transgenic mice engineered to express human antibody genes for fully human antibody discovery, licensed by more than 170 partners since its 2019 launch. Alloy has expanded beyond antibodies into T-cell receptor mimics, genetic medicines, and cell therapies, with AI/ML capabilities added through its 2021 DeepCDR acquisition. The company operates from Waltham, MA with additional sites in Athens GA, Cambridge UK, Basel, and Fujisawa, Japan.

What sets it apart

Sells access to pre-competitive discovery technology on deliberately partner-friendly terms — a January 2025 ATX-Gx licensing model with no annual access fee or development milestones — and reinvests 100% of profits into new platform development, positioning itself as an ecosystem enabler rather than a competitor to its partners' pipelines.

Funding history

1 round
EquityMar 31, 2026
Form D
+$30.0M$30.0M total

Latest SEC filings

via EDGAR · CIK 0001851943
Form D · Mar 31, 2026View on EDGAR

Products

1 tracked

ATX-Gx

Antibody discovery platform

A licensable platform of transgenic mouse strains engineered to express human antibody genes, producing robust immune responses with human-like immune repertoires for fully human therapeutic antibody discovery.

  • Multiple transgenic mouse strains expressing human antibody genes
  • Human-like immune repertoires with wild-type-strength immune responses
  • Licensing model without annual access fees or development milestones
  • Adopted by more than 170 partners, including large pharma and research institutions

Links

WebsiteLinkedInSEC EDGAR filings